Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on May 07, 2015 9:12pm
133 Views
Post# 23706669

RE:RE:Agoracom Forum

RE:RE:Agoracom ForumHi Jkj. Perhaps ther is room for Zenith but I sense that is a long way off unless they really have the patents and intellectual cpaital at this stage to command a high entry into an IPO and the share structure will be interesting.

If Don is right about their 8 year lead in epigenetics I could imaging companies out their wanting in on the action.

The webcast next week will be interesting with an explanation about Dr Cherrington. Seems to me like Zenith may have lost another full year in development. Or there is now a conflict of interest. Or Zenith is being repackaged back into RVX.

Who knows but I hope that Don has a plan for fast liquidity. Perhaps Shenzhen can develop Zenith epigenetic platforms quicker.

GLTA
Cheers
Toinv


Bullboard Posts